New treatment approach for severe immune system disorders

Targeting the immunoproteasome as a novel therapeutic strategy for hemophagocytic lymphohistiocytosis

NIH-funded research St. Jude Children's Research Hospital · NIH-10881951

This study is looking at a serious immune disorder called primary hemophagocytic lymphohistiocytosis (pHLH) to find new treatments that could help people with this condition by targeting a part of immune cells that might be involved in the disease.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-10881951 on NIH RePORTER

What this research studies

This research focuses on primary hemophagocytic lymphohistiocytosis (pHLH), a serious immune disorder that leads to severe inflammation and can be life-threatening. The study aims to develop new therapies targeting the immunoproteasome, a component of immune cells that processes proteins and may play a role in the disease's progression. By understanding how certain immune cells behave in pHLH, researchers hope to find more effective treatments that could improve patient outcomes. The approach involves both laboratory studies and potential clinical applications for patients suffering from this condition.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with primary hemophagocytic lymphohistiocytosis, particularly those who have not responded well to existing treatments.

Not a fit: Patients with other forms of hyperinflammation or those not diagnosed with pHLH may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatments for patients with pHLH, potentially reducing mortality and improving quality of life.

How similar studies have performed: While the approach of targeting the immunoproteasome is relatively novel, previous research has shown promise in similar immune disorders, indicating potential for success.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.